2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Toon Van Gorp, MD, PhD, discusses the efficacy of mirvetuximab soravtansine in FRα-positive platinum-resistant ovarian cancer after 30.5 months of follow-up.
“We looked at OS, PFS, and all the other efficacy end points, and it was clear that the benefit that we saw during the primary analysis in 2023 [with mirvetuximab soravtansine over chemotherapy] is still maintained [after long-term follow-up].”
Toon Van Gorp, MD, PhD, a gynecologic oncologist at Universitair Ziekenhuis Leuven in Belgium, discusses final data from the phase 3 MIRASOL trial (NCT04209855) evaluating mirvetuximab soravtansine-gynx (Elahere) in patients with folate receptor alpha (FRα)–positive platinum-resistant ovarian cancer.
Related Content: